No data available
No data available
BlueGnome was founded in in 2002 by a team of scientists who developed a novel mathematical technology for the analysis of genetic data following the sequencing of the human genome in 2000. Over the following 10 years BlueGnome has seen rapid growth and adoption of its technology and has become a leading provider of genetic solutions for the screening of chromosomal abnormalities in cytogenetics and IVF. This year BlueGnome was acquired by Illumina and is now a wholly owned subsidiary of Illumina - enhancing the company’s ability to establish integrated solutions in reproductive health and cancer.
Independent Consultant specialising in business start-up in Life Sciences, from Idea to commercialisation and/or investment. Incubation specialist, coaching, mentoring and organisational advisory service
Miranda Weston-Smith advises entrepreneurs, companies and universities on business development in healthcare and biotech. She is experienced in intellectual property negotiations, business planning and fund-raising. Starting a technology company, the book Miranda wrote while at Cambridge Enterprise, University of Cambridge is available at [email protected]. Miranda is a graduate in Natural Sciences, University of Cambridge, holds the AAT Diploma in Accounting, and is a Fellow of the Linnaean Society.
No data available
Established in May 2016, The AMR Centre is a key part of the UK’s response to the global threat from Antimicrobial Resistance. Based at Alderley Park, The AMR Centre is a joint private-public initiative to support/accelerate the development of new antibiotics and diagnostics through a fully integrated development capability, offering translational R&D from pre-clinical hits through to clinical proof of concept.
No data available
Informa Connect’s Life Science Partnering, Investment & Strategy teams' mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference portfolio in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today, our events (BIO-Europe, BIO-Europe Spring®, Biotech Showcase™, ChinaBio® Partnering Forum, Asia Bio Partnering Forum, LSX Europe, LSX Nordic, LSX USA, Investival Showcase EU, Investival Showcase USA, European Lifestars Awards, and BioEquity Europe) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.
Informa is a leading international Live B2B Events, B2B Digital Services, and Academic Markets Group. We champion specialists: connecting businesses and professionals with knowledge to help them learn more, know more and do more. Informa is a member of the FTSE 100 and works in over 30 countries.
For more information, please visit: https://informaconnect.com/partnering-investment-strategy/
Informa is a leading international Live B2B Events, B2B Digital Services, and Academic Markets Group. We champion specialists: connecting businesses and professionals with knowledge to help them learn more, know more and do more. Informa is a member of the FTSE 100 and works in over 30 countries.
For more information, please visit: https://informaconnect.com/partnering-investment-strategy/
Inivata is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment.. . Inivata works with leaders in industry and academic research to develop new clinical applications for ctDNA analysis which will bring real benefits to physicians, patients, pharmaceutical companies and payers. Inivata’s goal is to provide physicians with the information they need, to provide the best outcomes for patients and effective design for clinical trials.. . Inivata is based in Cambridge, UK and its scientific founders are leading figures in the ctDNA field: Nitzan Rosenfeld (Cancer Research UK Cambridge Institute, University of Cambridge), Tim Forshew (UCL Cancer Institute, University College London), James Brenton (Cancer Research UK Cambridge Institute, University of Cambridge) and Davina Gale (Cancer Research UK Cambridge Institute, University of Cambridge).. . The Company has a comprehensive understanding of cancer genomics and circulating DNA. It is applying its enhanced TAm-Seq approach and cutting-edge technologies to address critical clinical decision points in cancer care and cancer drug development, alongside pharmaceutical partners, leading clinicians and academic groups.